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Abstract
Background: Alcohol-related hospital admissions have doubled in the last ten years to > 1.2 m per year in England.
High-need, high-cost (HNHC) alcohol-related frequent attenders (ARFA) are a relatively small subgroup of patients,
having multiple admissions or attendances from alcohol during a short time period. This trial aims to test the
effectiveness of an assertive outreach treatment (AOT) approach in improving clinical outcomes for ARFA, and
reducing resource use in the acute setting.
Methods: One hundred and sixty ARFA patients will be recruited and following baseline assessment, randomly
assigned to AOT plus care as usual (CAU) or CAU alone in equal numbers. Baseline assessment includes alcohol
consumption and related problems, physical and mental health comorbidity and health and social care service use
in the previous 6 months using standard validated tools, plus a measure of resource use. Follow-up assessments at
6 and 12 months after randomization includes the same tools as baseline plus standard measure of patient
satisfaction. Outcomes for CAU + AOT and CAU at 6 and 12 months will be compared, controlling for pre-specified
baseline measures. Primary outcome will be percentage of days abstinent at 12 months. Secondary outcomes
include emergency department (ED) attendance, number and length of hospital admissions, alcohol consumption,
alcohol-related problems, other health service use, mental and physical comorbidity 6 and 12 months post
intervention. Health economic analysis will estimate the economic impact of AOT from health, social care and
societal perspectives and explore cost-effectiveness in terms of quality adjusted life years and alcohol consumption
at 12-month follow-up.
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Discussion: AOT models piloted with alcohol dependent patients have demonstrated significant reductions in
alcohol consumption and use of unplanned National Health Service (NHS) care, with increased engagement with
alcohol treatment services, compared with patients receiving CAU. While AOT interventions are costlier per case
than current standard care in the UK, the rationale for targeting HNHC ARFAs is because of their disproportionate
contribution to overall alcohol burden on the NHS. No previous studies have evaluated the clinical and cost-
effectiveness of AOT for HNHC ARFAs: this randomized controlled trial (RCT) targeting ARFAs across five South
London NHS Trusts is the first.
Trial registration: International standard randomized controlled trial number (ISRCTN) registry: ISRCTN67000214,
retrospectively registered 26/11/2016.
Keywords: Alcohol, Dependence, Frequent attenders, Assertive outreach treatment, Randomized controlled trial,
Multimorbidity, High need high cost
Background
Worldwide, alcohol use was the seventh leading risk fac-
tor for both deaths and DALYs (Disability-Adjusted Life
year) in 2016, accounting for 2.2% of female deaths and
6.8% of male deaths. In 2016, alcohol use led to 2.8 mil-
lion deaths worldwide and was the leading risk factor for
premature death and disability among people aged 15–
49 years. Alcohol use accounts for nearly 10% of global
deaths among populations aged 15–49 years [1].
In the UK, alcohol use disorders are a major public
health challenge: it is the leading cause of preventable dis-
ability in working age men [2, 3] and the third greatest risk
factor for years lived with disability [4]. Deaths from liver
disease have increased by over 400% since the 1970s in
the UK [5], and predicted to overtake cardiovascular dis-
ease as the leading cause of death by 2021 [6].
The UK Department of Health estimates that alcohol
costs the NHS in England £3.5bn per annum, 80% of
which is incurred in inpatient and emergency care costs
[7]. However, the wider annual costs to society in England
are estimated to be considerably greater at £21bn, £11bn
of which is incurred by the criminal justice system [8].
Alcohol-related hospital admissions have doubled in
the last 10 years to over 1.1 m per annum in England, a
quarter (337,000) of which were for conditions wholly
attributable to alcohol [9]. Reducing alcohol related ad-
missions is a key public health target and is an indicator
in the Public Health Outcomes Framework [10]. High-
need, high-cost (HNHC) alcohol related frequent at-
tenders (ARFAs) are a subgroup of all patients with
alcohol-related hospital admissions and are characterised
by having multiple hospital admissions or attendances
caused by alcohol1 during a relatively short time period.
Whilst there is no single universal definition for an
ARFA, for the purposes of this trial we defined an ARFA
as someone who has had two or more admissions in any
of the participating NHS trusts for at least one wholly
attributable alcohol diagnoses within a 1 year period,
OR; has had at least ten presentations to an emergency
department in any of the participating NHS trusts within
a 1 year period, OR; has at least four presentations to an
emergency department in any of the participating NHS
trusts within a month, OR; has been admitted at least
once for a wholly attributable alcohol diagnosis and had
at least four presentations to an emergency department
in any of the participating NHS trusts within a 1 year
period.
Previous studies show that the HNHC ARFA patient
group typically have high levels of multimorbidity, in-
cluding both physical and mental illness, social isolation,
poor quality of life, unstable housing or homelessness,
high criminal justice involvement, unemployment and
living on benefits [11]. Notably, they either have poor or
no engagement with existing specialist alcohol treatment
services. Their Accident and Emergency Department
(A&E) attendance is frequent, often due to not being
registered with a General Practitioner (GP), and they
have frequent emergency hospital admissions to both
acute and mental health beds. Qualitative research has
also identified that as a group ARFAs experience high
levels of stigma and social exclusion [12].
An intensive assertive outreach treatment (AOT) inter-
vention has been developed to target the patients who
have the highest alcohol related hospital attendance. AOT
is based on a model of community service provision ori-
ginally designed for people with severe mental illness
(SMI) and was first pioneered by the work of Stein and
Test (1980) [13]. AOT emphasises active engagement over
an extended period [14, 15] and has several features which
distinguish it from usual care, including: (i) rapid access to
services, (ii) a small caseload, (iii) a high ratio of commu-
nity to office-based appointments, (iv) assertive engage-
ment (e.g. with multiple attempts) and (v) a shared care
approach, with care coordinators working within a multi-
disciplinary team that meets frequently [16, 17]. In adult
1Caused by alcohol means that one of the given ICD10 diagnoses in
hospital records can be wholly attributable to alcohol.
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mental health care, AOT (sometimes also referred to as
Assertive Community Treatment) is an extensively
researched and widely used model of care for treating dif-
ficult to engage patients with severe and enduring mental
illness. AOT and its elements have also been used in the
treatment of alcohol dependence [18, 19] which clinically,
like severe and enduring mental illness, also often presents
as a chronic relapsing disorder with high public health
costs [20–25]. An AOT model implemented with alcohol
dependent patients, demonstrated significant reductions
in alcohol consumption and use of unplanned NHS care,
as well as increased engagement with alcohol treatment
services, compared with patients receiving care as usual
[14]. A national survey of AOT services for ARFAs in
2017 [21] found 76 services across England offering AOT
for ARFAs between December 2015 and June 2016. The
majority included a multi-disciplinary team and offered
extended support including advice on housing, mental
and physical health in addition to alcohol treatment, how-
ever there was considerable variation amongst the models
of care delivered and no previous RCTs have evaluated
their clinical effectiveness and cost-effectiveness.
While AOT interventions are more costly per case
than current standard care in the UK, the rationale for
targeting HNHC ARFAs is that they incur a dispropor-
tionately high amount of the overall alcohol burden on
the NHS. Hence the potential savings to the NHS, as
well as to wider social and criminal justice services, from
a successful intervention outcome are greater than other
less intensive interventions for less complex patients.
Methods
Aim
This randomised controlled trial will assess the clinical
and cost-effectiveness of care as usual (CAU) plus AOT
compared with CAU alone for adults who have frequent
alcohol related admissions.
Objectives
1. To conduct a randomised controlled trial of CAU +
AOT versus CAU in a sample of alcohol related
frequent attenders in five NHS trusts in South East
London.
2. To evaluate the effectiveness and cost-effectiveness
of CAU +AOT versus CAU alone in ARFAs to
acute and mental health inpatient care.
3. To describe the characteristics and health and
social care needs of ARFAs.
4. To identify potential mechanisms of action of AOT
and identify patient sub-groups for whom AOT is
more effective.
Primary hypothesis
 CAU + AOT will be more effective than CAU alone
in increasing the proportion of days abstinent from
alcohol, measured by the Time Line Follow Back
(TLFB) form 90, at 12 months follow-up.
Secondary hypotheses
 CAU + AOT will be cost-effective compared with
CAU alone at 12 months follow-up.
 CAU + AOT will reduce unplanned health care
utilisation including admissions to Emergency
Departments (ED) and acute and mental health
inpatient care compared to CAU alone.
 CAU + AOT will increase engagement with
specialist addiction and recovery services compared
to CAU alone.
 Addiction treatment engagement, readiness to
change and therapeutic alliance will moderate
treatment effectiveness.
Assertive outreach treatment intervention
Patients in the intervention arm of the study will receive
AOT in addition to usual care. AOT will incorporate the
following elements [14]:
(i) Each AOT practitioner should have a maximum
caseload of 15 AOT patients.
(ii) Care provided by a multidisciplinary team
(including psychiatrists, community addiction
nurses, substance use disorder specialists,
community support workers).
(iii)Frequent and regular contact between practitioner
and patient (at least once a week predominantly in
patients’ homes and local community settings).
(iv)Assertive engagement – persistent and repeated
attempts by the practitioner to make contact, with
the emphasis being on maintaining contact and
building relationships.
(v) Content of sessions will focus on both health and
social care needs – including accommodation,
leisure, occupation, and physical and mental health,
with an emphasis on a patient-led agenda.
(vi) Flexibility – practitioners should work flexibly with
patients’ goals and include those which are less
related to the addiction. The AOT model has
abstinence from alcohol as its ultimate clinical goal.
However, whilst all treatment aspires to achieve full
recovery, it can be an unrealistic short-term goal
for more severely dependent drinkers with complex
social support needs plus multiple comorbidities, in
which case a reduction in harmful drinking will be
a more realistic goal.
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(vii) Openness – practitioners explain their role and
aims in care planning and in visits.
(viii) Practitioners operate more broadly than in their
usual professional roles to provide a wide range of
support to patients.
(ix)Extended care – AOT will be provided for a period
of 1 year during which patients will be introduced
to other existing community services who will
ultimately provide them with on-going support in
the longer-term.
AOT will be used to proactively engage with ARFA
patients, to assess their physical and mental health and
wider social needs, then to develop shared treatment
goals, and to facilitate and coordinate engagement with
the relevant care and support to address their multiple
presenting needs. The AOT will mainly take place either
in the patient’s home or local community settings. A
treatment manual has been developed by the research
team as part of a previous clinical trial [11].
Training
All staff who will be delivering the AOT service will par-
ticipate in a training programme, focusing on:
 Key features of AOT and how it should be delivered
in the context of alcohol-related frequent attenders,
including techniques to maximise engagement.
 Overview of the research trial, inclusion and
exclusion criteria, obtaining consent, the assessment
tools being used in the trial, maintaining contact
logs.
 Safety whilst working in the community.
In addition, each member of staff will spend a day sha-
dowing mental health assertive outreach staff participating
in community and home visits with patients. This will also
provide staff with the opportunity to ask questions around
practical issues associated with delivering AOT.
Control intervention
All participants in the control arm of the study will re-
ceive CAU i.e. routine clinical practice, so that the hy-
pothesis that CAU +AOT is more effective than CAU
alone can be tested. CAU typically involves treatment of
presenting physical or mental health problems and refer-
ral to specialist addiction services for ongoing help with
alcohol related problems. Patients receiving CAU have
access to medical detoxification, psychological interven-
tions targeting drinking behaviour and aftercare, which
are usually provided by specialist addiction services. But
in contrast to AOT, the emphasis will be on the patient’s
own motivation to engage with available services. Spe-
cialist input from addictions psychiatry, clinical
psychology and social work may also be a part of CAU
but the assertive and regular nature of contacts in AOT
does not feature.
Intervention fidelity
Prior to delivering AOT all staff will undergo training as
outlined above. Practitioners will attend regular weekly
multidisciplinary clinical meetings and regular individual
and group supervision to ensure that the intervention is
being delivered in a consistent manner by all practitioners,
in line with the characteristic features of AOT. Staff pro-
viding care to patients will be asked to complete a log of
the contacts they have with patients and the care pro-
vided. This will include the nature of the contact (face-to-
face meetings, telephone calls, text messages and emails),
setting (home, community, clinical), the focus of the con-
tact (mental health, physical health, housing, finance etc),
duration of the contact, and the member of staff involved.
Participants
Inclusion criteria
i) Age 18 years or over.
ii) Able to understand English sufficiently well to
obtain informed consent and complete the
assessment instruments.
iii) has had two or more admissions in any of the
participating NHS trusts for at least one wholly
attributable alcohol diagnoses within a 1 year
period, OR; has had at least ten presentations to an
emergency department in any of the participating
NHS trusts within a 1 year period, OR; has had at
least four presentations to an emergency
department in any of the participating NHS trusts
within a month, OR; has been admitted at least
once for a wholly attributable alcohol diagnosis and
had at least four presentations to an emergency
department in any of the participating NHS trusts
within a 1 year period.
iv) International Classification of Diseases version 10
(ICD-10) diagnosis of alcohol dependence.
v) Willing to provide informed consent to participate
in the trial.
vi) A resident of Lambeth and Southwark and admitted
to one of the five participating NHS Trusts.
Exclusion criteria
i) Unable to give informed consent.
ii) Experiencing severe mental of physical illness likely
to preclude active participation in the treatment or
research follow up.
iii) Already in receipt of assertive outreach services or
participation in another trial.
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iv) Has a severe cognitive impairment as determined
by Mini Mental State Examination score of ≤10
[22].
v) Has a history of violence to staff or is registered
under multi-agency public protection arrangements
(MAPPA).
vi) Dependence on opiates or stimulants.
vii) Street homeless or has no recourse to public funds.
Identification and recruitment of potential participants
The AOT clinical team will work with informatics teams in
the five NHS trusts (King’s College Hospital (KCH)-, Guy’s
and St Thomas’ (GST)-, South London and Maudsley
(SLaM)- and St George’s Healthcare (STG)- NHS Founda-
tion Trusts; and Lewisham and Greenwich (LGT) NHS
Trust) to identify HNHC ARFA based on primary or sec-
ondary clinical diagnoses of alcohol related admissions and
number of admissions or emergency department atten-
dances in the previous 12months. This will also include the
use of the clinical research information system (CRIS)
within SLaM. The clinical team will also have access to
electronic clinical records and discuss potentially eligible
patients with clinicians in inpatient units in the five trusts,
and the Alcohol Care Teams at KCH, STG and GST, to
identify additional patients who meet the study criteria but
are not captured by diagnostic criteria in electronic records.
Once potentially eligible patients have been identified,
they will be contacted by the AOT clinical team and
assessed for eligibility and informed about the potential to
participate in the trial. They will be given the Patient In-
formation Sheet and the trial will be explained verbally.
Patients will be encouraged to ask questions or consult
carers, relatives or their GP. If willing to proceed, eligible
patients will be introduced to a member of the research
team who will again explain the trial, confirm the patient’s
eligibility, and obtain informed consent. The minimum
period of time between informing the patients of the trial
and obtaining consent will be 24 h. Patients unwilling to
take part will be offered the standard CAU, including re-
ferral to local specialist addiction services.
Patients who provide informed consent will undergo a
baseline research assessment conducted by the research
team and will be randomised using an electronic trial man-
agement tool. In order to maintain blinding of researchers,
the treatment allocation will be provided only to the AOT
clinical team who will then initiate AOT treatment or refer-
ral to specialist addictions services as appropriate.
Baseline assessment
(i) Socio-demographic information: age, sex, ethnicity,
marital status, living arrangement, children, living
arrangements of children, education.
(ii) Drinking in the previous 90 days – TLFB 90I [23].
The TLFB is a validated interview method to
measure alcohol consumption in the previous 90
days and is the gold standard outcome measure in
alcohol treatment research. Percentage days
abstinent, units of alcohol per drinking day (1 UK
unit = 8 g alcohol), time to first alcoholic drink,
relapse to any drinking and relapse to heavy
drinking (8+/6+ units for males/females on a single
occasion) will be computed.
(iii)History of drug use – TLFB.
(iv)Alcohol related problems - Alcohol Problems
Questionnaire (APQ) [24]. The APQ is a validated
46-item questionnaire assessing potential problems
with psychological, physical, social, legal, employ-
ment, relationships and parenting that may be expe-
rienced due to alcohol.
(v) Severity of alcohol dependence - Severity of Alcohol
Dependence Questionnaire (SADQ) [25]. The SADQ
is a validated 20-item self-complete questionnaire
containing items representing five domains of the al-
cohol dependence syndrome: (i) physical withdrawal
signs (ii) psychological withdrawal signs (iii) with-
drawal relief drinking (iv) tolerance (v) reinstatement
following a period of abstinence.
(vi)Health related quality of life – EuroQol 5
dimensions 5 levels (EQ-5D-5 L) [26]. The EQ-5D-
5 L consists of five dimensions (mobility, self-care,
usual activities, pain/discomfort and anxiety/depres-
sion) scored on five levels (no problems, slight
problems, moderate problems, severe problems and
extreme problems). The EQ-5D-5 L is an extension
of the original 3-level EQ-5D and has been shown
to be valid [27].
This version of EuroQol measure of health-related
quality of life capable of generating quality adjusted life
years (QALYs) for use in economic evaluations.
(vii) Health Related Quality of life – Short-form-12
(SF-12) [28]-a 12 item subset of Short form-36, for
measuring self-reported health related quality of
life.
(viii)Motivation to change - Readiness to Change -
Treatment version [29]- a 12 item questionnaire
used to assess the subject’s stage of change.
(ix)Social network involvement - Important People and
Activities Inventory [30]. This measure gathers
information regarding general and alcohol-specific
types of support. This scale contains 11 indices
which in combination create a summary measure
for predicting alcohol use,
(x) Resource use – Adult Service Use Schedule (AD-
SUS) [31] The AD-SUS is a resource use measure
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designed for and applied to mental health popula-
tions, including drug and alcohol populations.
Follow up assessments
Six and twelve months after randomisation, all partici-
pants will be followed up (see Fig. 1). A research worker,
blind to treatment allocation, will arrange a convenient
time to meet with the participant. Baseline measures
(items i-x above) will be repeated in addition to:
(xi)Therapeutic relationship – Scale to assess
therapeutic relationship (STAR) [32] completed at
12 months follow-up. Therapeutic relationship (or
alliance) has been found to predict clinical outcome
across a range of mental disorders including alcohol
dependence. This will be used as an additional
process measure to assess the impact of therapeutic
relationship on medication adherence and clinical
outcome.
Maintaining the researcher’s blindness to treatment al-
location is an acknowledged problem in psychosocial
intervention trials in comparison to placebo controlled
medication trials. In order to reduce the risk of partici-
pants inadvertently revealing the treatment allocation,
researchers will advise participants not to discuss their
ongoing treatment arrangements or the identity of their
key worker or service and will conduct the TLFB meas-
ure before discussing service utilisation as in a previous
trial [11].
Randomisation and blinding
Randomisation to one of the two treatment arms will
take place after consent and baseline data have been
Fig. 1 SPIRIT diagram for the schedule of enrolment, interventions, and assessments
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collected, by a remote electronic allocation system. Once
baseline data has been submitted on the electronic de-
vice by the researcher, the system will email the rando-
mised allocation to a member of the clinical team. The
researchers will be blind to the allocated intervention
throughout the trial. The online system will be devel-
oped and maintained by Codeface Ltd. Randomisation
will be stratified by site and severity of alcohol depend-
ence (< = 30 and > 30), as measured by the Severity of
Alcohol Dependence Questionnaire (SADQ).
Sample size and power
The primary outcome of the RCT is percent days abstin-
ent using validated Time-Line Follow-Back (TLFB)
interview method over a 90-day reference period at 12
months post-recruitment, which is the gold standard in
alcohol treatment research. Similar studies have used ef-
fect sizes of 0.3–0.5 in their sample size calculations
[14]. We propose using an effect size of 0.4, alongside
type 1 error rate, α = 0.05 and type 2 error rate, β = 0.8
and using a two-sided test. This indicates a sample size
of 64 patients each in intervention and control group in-
cluded in the analysis at the primary end-point. In order
to address potential loss to follow-up we have incorpo-
rated a loss of 20%, larger than previous studies such as
ACTAD that had a loss to follow-up of 7% at 12 months
but smaller than UKATT [33] that has a 28% loss at 12
months. This inflates the required sample size at recruit-
ment to 80 in each group a total of 160 at baseline with
the expectation that at least 64 in each group, a total of
128, will be followed up at 12 months.
Statistical analysis
Our analysis of the primary outcome measure involves a
comparison of the effectiveness of AOT + CAU versus
CAU alone. Analysis will be conducted by intention to
treat principles and the primary outcome measure will
be percent days abstinent in the 90 days prior to 12
months follow up. AOT + CAU will be compared to
CAU using analysis of covariance including stratification
variables; SADQ and site as covariates. Multiple imput-
ation and sensitivity analysis will be employed to assess
the impact of missing data. Results will be presented as
mean differences with associated 95% confidence inter-
vals. Secondary analysis will address drinking and other
outcomes at 6 and 12 months using appropriate model-
ling approaches and these will be adjusted for covariates;
SADQ, site, age and gender. We will explore the associ-
ation between engagement in treatment (measured by
cumulative number of days in AOT and specialist alco-
hol treatment), readiness to change, and therapeutic alli-
ance, and drinking outcomes using a linear regression
adjusted for known confounders. As with most trials the
analysis plan will be refined throughout the course of
the study and the final analysis plan prepared and agreed
by the research team and Trial Steering Committee.
Economic evaluation
The economic evaluation will estimate the costs and
cost-effectiveness of CAU +AOT compared with CAU
alone over the 12-month follow-up. The primary eco-
nomic evaluation will take a societal perspective includ-
ing the use of all health and social care services, plus
productivity losses (time off work due to illness) and
criminal justice sector resources, known to be of particu-
lar importance in drug and alcohol populations. Whilst
the NHS/personal social services perspective is generally
preferred by National Institute for Health and Care Ex-
cellence (NICE), the inclusion of criminal justice sector
resources is recognised by NICE as an appropriate ex-
tension for drug and alcohol treatment evaluations [34].
Resource use data is being measured using a version of
the AD-SUS which was developed for addiction and al-
cohol use disorder populations in previous research [31].
The AD-SUS is completed in interview with participants
at baseline (covering the previous 6 months) and at 6
and 12-month follow-up (covering the period since pre-
vious interview). Appropriate unit costs will be applied
to all resource elements reported by participants to cal-
culate the total cost per participant. The AOT interven-
tion will be costed directly, taking a micro-costing
approach and nationally applicable unit costs will be ap-
plied to all other health and social care services used (for
example, NHS Trust reference costs and the Personal
Social Services Research Unit Costs of Health and Social
Care compendium [35]. Criminal activity will be costed
using existing Home Office estimates [36], uprated as
appropriate, unless newer estimates become available.
Productivity losses will be valued using the human cap-
ital approach, which involves multiplying time off work
due to illness by an appropriate wage rate [37].
Health utility is being measured with the EQ-5D-5 L
(five dimensions, five levels) version of the EuroQol meas-
ure of health-related quality of life. The EQ-5D is a meas-
ure capable of generating quality adjusted life years
(QALYs) for use in economic evaluations and will be used
in the primary economic evaluation exploring cost-
effectiveness in terms of cost per QALY. Responses will
generate health states that utility weights can then be ap-
plied to and QALYs will be calculated using the total area
under the curve approach. EQ-5D-5 L is a more sensitive
version of the EQ-5D, measuring health-related quality of
life and has been used extensively in previous alcohol
studies in the UK (e.g. UKATT Research Team [33]).
Two economic evaluations will be carried out: a cost-
utility analysis using quality adjusted life years calculated
from the EQ-5D-5 L [38] using the area under the curve
approach [39] (primary) and a cost-effectiveness analysis
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using the primary clinical measure of the RCT, percentage
days abstinent in the past 90 days using the Time Line
Follow Back interview (secondary). Cost-effectiveness will
be assessed through the calculation of incremental cost-
effectiveness ratios (ICER) – the additional costs of one
intervention compared to another divided by the add-
itional effects of one intervention compared to another
[40]. Uncertainty will be represented by cost-effectiveness
acceptability curves [41]. Analyses will use standard para-
metric tests with mean differences and 95% confidence in-
tervals generated from bootstrap regressions (1000
replications) to account for non-normal distribution com-
mon to economic data [42, 43]. In line with the clinical
analyses, all economic analyses will be conducted by
intention to treat principles with stratification variables,
SADQ and site as covariates and multiple imputation by
chained equations to account for missing data. Sensitivity
analysis will explore the impact of missing data using a
complete case approach and the impact of perspective tak-
ing the narrower NHS/personal social services.
Protocol amendments
The inclusion criteria changed during recruitment to
also include patients with alcohol related frequent emer-
gency department attendances.
Discussion
AOT models piloted with alcohol dependent patients have
demonstrated significant reductions in alcohol consump-
tion and use of unplanned NHS care, with increased en-
gagement with alcohol treatment services, compared with
patients receiving CAU. While AOT interventions are
more costly per case than current standard care in the
UK, the rationale for targeting HNHC ARFA is because of
their disproportionate contribution to the overall alcohol
burden on the NHS. No previous studies have evaluated
the clinical and cost-effectiveness of AOT for HNHC
ARFA: this RCT targeting ARFA across five South
London NHS Trusts is the first to do so.
The inclusion criteria changed during recruitment to
also include patients with alcohol related frequent emer-
gency department attendances. In practice, this resulted
in an increase in recruitment across the participating
NHS trusts. Assessments completed by the AOT clinical
team during the first 6 months of recruitment revealed
that some participants had few inpatient hospital admis-
sions in a year, but frequently attended an emergency
department for alcohol related reasons, often choosing
to leave before discharge. A high number of emergency
department attendances with no resulting inpatient hos-
pital admission incur costs of similar proportions to an
inpatient hospital admission which are of importance to
the economic analysis undertaken in the trial. A full
amendment was approved to recruit from this patient
population.
As far as we are aware, this is the first randomised
controlled trial to evaluate AOT approaches for high
cost high need alcohol related frequent attenders. The
main strength of the study is that participants are ran-
domized to receive the intervention or care as usual
(control). By randomly allocating ARFA to control or
intervention groups the impact of confounders (such as
age, gender, ethnicity, levels of engagement with other
services) as a source of bias are equally distributed be-
tween the intervention and control groups, and therefore
minimised. The blinding of the researchers to treatment
allocations reduces reporting bias. The economic ana-
lysis is carried out to include criminal justice sector re-
sources which is recognised as an appropriate extension
for drug and alcohol treatment evaluations.
Limitations include the potential of loss of subjects to
follow-up. To reduce this risk, most data collection takes
place in the subject’s home or community environment.
In this hard to reach cohort of interest, if loss to follow-
up does occur, using multiple imputation to account for
missing data will help minimize this impact. Another
potential challenge is maintaining the researcher’s blind-
ness to treatment allocation, which is an acknowledged
problem in psychosocial intervention trials. Researchers
will advise participants not to discuss their ongoing
treatment arrangements or the identity of their key
worker or service and will conduct the TLFB measure
before discussing service utilisation. The clinical com-
plexity of the HNHC ARFA means that many experience
mental health problems, homelessness and drug addic-
tion and a limitation of our study is that by the nature of
our exclusion criteria, we are not testing the efficacy of
AOT on certain subgroups of the HNHC ARFA popula-
tion. Consideration will need to be given as to whether
the full extent of clinical and economic benefits have
been completely realised within the 12month follow up
period; and how rates of death in both groups and sign-
posting to health services impact on overall costs.
Trial status
Analysis is ongoing.
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